These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22145093)

  • 1. Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer.
    Lacher MD; Pincheira RJ; Castro AF
    Small GTPases; 2011 Jul; 2(4):211-216. PubMed ID: 22145093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
    Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
    Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
    Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino Acid-Mediated Intracellular Ca
    Amemiya Y; Nakamura N; Ikeda N; Sugiyama R; Ishii C; Maki M; Shibata H; Takahara T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
    Bhatia B; Northcott PA; Hambardzumyan D; Govindarajan B; Brat DJ; Arbiser JL; Holland EC; Taylor MD; Kenney AM
    Cancer Res; 2009 Sep; 69(18):7224-34. PubMed ID: 19738049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
    Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
    Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
    Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
    Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.
    Short JD; Houston KD; Dere R; Cai SL; Kim J; Johnson CL; Broaddus RR; Shen J; Miyamoto S; Tamanoi F; Kwiatkowski D; Mills GB; Walker CL
    Cancer Res; 2008 Aug; 68(16):6496-506. PubMed ID: 18701472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
    Kwiatkowski DJ; Manning BD
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospholipase D1 is an effector of Rheb in the mTOR pathway.
    Sun Y; Fang Y; Yoon MS; Zhang C; Roccio M; Zwartkruis FJ; Armstrong M; Brown HA; Chen J
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8286-91. PubMed ID: 18550814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
    Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
    Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.
    Wang Y; Hong X; Wang J; Yin Y; Zhang Y; Zhou Y; Piao HL; Liang Z; Zhang L; Li G; Xu G; Kwiatkowski DJ; Liu Y
    Oncogene; 2017 Feb; 36(6):756-765. PubMed ID: 27399332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J; Wu S; Wu CL; Manning BD
    Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into TSC complex assembly and GAP activity on Rheb.
    Yang H; Yu Z; Chen X; Li J; Li N; Cheng J; Gao N; Yuan HX; Ye D; Guan KL; Xu Y
    Nat Commun; 2021 Jan; 12(1):339. PubMed ID: 33436626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC).
    Feliciano DM
    Front Neuroanat; 2020; 14():39. PubMed ID: 32765227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
    Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
    BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.